Literature DB >> 6192710

Senile macular degeneration: review of epidemiologic features.

F L Ferris.   

Abstract

Senile macular degeneration is a leading cause of visual loss in the United States, England, and probably many other industrialized countries. The clinical manifestations of this disease include: drusen, atrophy of the retinal pigment epithelium, serous detachment of the retinal pigment epithelium, subretinal neovascularization, and disciform scars. Standardized techniques for defining these manifestations of senile macular degeneration are necessary for epidemiologic study of this disease. Such standardization is facilitated by the use of fundus photographs. If a visual acuity deficit is included in the definition of senile macular degeneration, care must be taken to assure that senile macular degeneration is responsible for the decreased vision. The Framingham Eye Study provides the best senile macular degeneration prevalence data. The rapid increase in prevalence of senile macular degeneration after the fifth decade is demonstrated in this study and is consistent with other studies. In fact, increasing age has the strongest association with senile macular degeneration of any of the risk factors considered to date. Many other possible risk factors have been identified but further investigation is necessary to verify these associations.

Entities:  

Mesh:

Year:  1983        PMID: 6192710     DOI: 10.1093/oxfordjournals.aje.a113624

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  45 in total

1.  "Oxidative protector" enzymes in the macular retinal pigment epithelium of aging eyes and eyes with age-related macular degeneration.

Authors:  R N Frank
Journal:  Trans Am Ophthalmol Soc       Date:  1998

Review 2.  Macular pigment and age related macular degeneration.

Authors:  S Beatty; M Boulton; D Henson; H H Koh; I J Murray
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

3.  Radiotherapy for isolated occult subfoveal neovascularisation in age related macular degeneration: a pilot study.

Authors:  G Donati; D Soubrane; M Quaranta; G Coscas; G Soubrane
Journal:  Br J Ophthalmol       Date:  1999-06       Impact factor: 4.638

4.  Successful photodynamic therapy for subretinal neovascularisation due to Sorsby's fundus dystrophy: 1 year follow up.

Authors:  S C Wong; K C S Fong; N Lee; K Gregory-Evans; C Y Gregory-Evans
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

5.  Impact of photodynamic therapy on quality of life of patients with age-related macular degeneration in Korea.

Authors:  Jinhyun Kim; Hyung Woo Kwak; Won Ki Lee; Ha Kyoung Kim
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

6.  Visible light and risk of age-related macular degeneration.

Authors:  H R Taylor; B Muñoz; S West; N M Bressler; S B Bressler; F S Rosenthal
Journal:  Trans Am Ophthalmol Soc       Date:  1990

7.  Long term results after transpupillary thermotherapy in eyes with occult choroidal neovascularisation associated with age related macular degeneration: a prospective trial.

Authors:  U Stolba; I Krebs; P D Lamar; T Aggermann; D Gruber; S Binder
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

8.  A primate model for age related macular drusen.

Authors:  G M Hope; W W Dawson; H M Engel; R J Ulshafer; M J Kessler; M B Sherwood
Journal:  Br J Ophthalmol       Date:  1992-01       Impact factor: 4.638

9.  The prevalence of eye disease in Leicester: a comparison of adults of Asian and European descent.

Authors:  B N Das; J R Thompson; R Patel; A R Rosenthal
Journal:  J R Soc Med       Date:  1994-04       Impact factor: 5.344

10.  Low glutathione reductase and peroxidase activity in age-related macular degeneration.

Authors:  S M Cohen; K L Olin; W J Feuer; L Hjelmeland; C L Keen; L S Morse
Journal:  Br J Ophthalmol       Date:  1994-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.